kabutan

EIKEN CHEMICAL CO.,LTD.(4549) Summary

4549
TSE Prime
EIKEN CHEMICAL CO.,LTD.
2,455
JPY
+30
(+1.24%)
Dec 12, 3:30 pm JST
15.75
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
21.4
PBR
1.85
Yield
2.36%
Margin Trading Ratio
2.65
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
2,454 JPY 15.78 USD
Previous Close Dec 11
2,425 JPY 15.53 USD
High Dec 12, 9:50 am
2,475 JPY 15.90 USD
Low Dec 12, 9:00 am
2,412 JPY 15.51 USD
Volume
83,700
Trading Value
0.21B JPY 1.32M USD
VWAP
2455.33 JPY 15.76 USD
Minimum Trading Value
245,500 JPY 1,575 USD
Market Cap
0.08T JPY 0.55B USD
Number of Trades
408
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
413
1-Year High Aug 1, 2025
1,407
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 41,600 69,000 1.66
Nov 28, 2025 41,100 65,000 1.58
Nov 21, 2025 40,400 57,900 1.43
Nov 14, 2025 39,700 50,600 1.27
Nov 7, 2025 42,300 42,700 1.01
Company Profile
EIKEN CHEMICAL CO.,LTD. is a leading manufacturer of clinical diagnostic reagents, with a high market share in fecal occult blood test reagents. The company also produces reagents for microbiology, genetic testing, and urinalysis.
Sector
Pharmaceuticals
EIKEN CHEMICAL CO.,LTD. specializes in the manufacture and sale of clinical diagnostic reagents as its core business. The company holds the top domestic market share in fecal occult blood test reagents. It operates both domestically and internationally, with a consolidated subsidiary in China called Eiken China Co., Ltd. This Chinese subsidiary engages in contract manufacturing of the company's diagnostic reagents and the purchase, manufacture, and sale of diagnostic products. The group as a whole focuses on the diagnostic reagent business, maintaining a strong position in the domestic market while expanding overseas. International sales account for approximately one-quarter of the company's total revenue. EIKEN CHEMICAL CO.,LTD. contributes to improving the quality of healthcare by leveraging its technological expertise and product development capabilities in the field of clinical diagnostic reagents.